Gerui Pharmaceuticals-B announced its interim financial report, showing that for the six months ended June 30, 2024, the company did not record any revenue, and the loss for the period expanded to RMB 130.3 million, an increase of 687.0% compared to the same period last year. The loss was mainly due to the increase in research and development costs. The company's research and development expenses increased from approximately RMB 92.3 million to around RMB 132.4 million. The company incurred no sales costs during the reporting period, as the market demand for lopinavir products contracted due to effective control of the COVID-19 epidemic in mainland China. Other income and gains decreased from approximately RMB 75.0 million to around RMB 49.0 million. The comprehensive loss for the period was RMB 121.6 million. As of June 30, 2024, the company's cash and cash equivalents were approximately RMB 2,117.2 million, expected to be sufficient to support research and development activities and operations until 2028.

Gerui Pharmaceuticals-B announced its interim financial report, showing that for the six months ended June 30, 2024, the company did not record any revenue, and the loss for the period expanded to RMB 130.3 million, an increase of 687.0% compared to the same period last year. The loss was mainly due to the increase in research and development costs. The company's research and development expenses increased from approximately RMB 92.3 million to around RMB 132.4 million. The company incurred no sales costs during the reporting period, as the market demand for lopinavir products contracted due to effective control of the COVID-19 epidemic in mainland China. Other income and gains decreased from approximately RMB 75.0 million to around RMB 49.0 million. The comprehensive loss for the period was RMB 121.6 million. As of June 30, 2024, the company's cash and cash equivalents were approximately RMB 2,117.2 million, expected to be sufficient to support research and development activities and operations until 2028.